In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Celgene Flexes Its Muscles

Executive Summary

In five short years, Celgene has used the cash from the blockbuster success of its flagship product Revlimid to pursue a wide range of deals for revenues now and new markets later. Its homegrown R&D has created a bountiful late-stage pipeline. It’s projecting even more Revlimid success in the next few years. So why aren’t investors buying?
Advertisement

Related Content

Celgene Oncology Strategy: Seizing The Immuno-Hematology Opportunity
Celgene’s Bet On Abraxis Helps Spur Host Of Nanomedicine Start-Ups
Nanomedicine: Will It Get Big?
Sanofi/Genzyme: Emblematic of What Big Pharma's Buying Now
Sanofi/Genzyme: Emblematic of What Big Pharma's Buying Now
Gilead Takes Calistoga To Boost Cancer Effort
Despite Celgene's Abraxane Stock, Trading Earn-Outs Is The Exception Not The Rule
Despite Celgene's Abraxane Stock, Trading Earn-Outs Is The Exception Not The Rule
Biotechs Target Cancer Metabolism
Celgene Teams Up With Agios In Long-Term Cancer Metabolism Pact

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

IV003605

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel